Correlation Between Cidara Therapeutics and Protalix Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Cidara Therapeutics and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cidara Therapeutics and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cidara Therapeutics and Protalix Biotherapeutics, you can compare the effects of market volatilities on Cidara Therapeutics and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cidara Therapeutics with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cidara Therapeutics and Protalix Biotherapeutics.

Diversification Opportunities for Cidara Therapeutics and Protalix Biotherapeutics

0.87

Correlation Coefficient

Cidara Therapeutics  Protalix Biotherapeutics

Very poor diversification

The 3 months correlation between Cidara and Protalix is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Cidara Therapeutics and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Cidara Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cidara Therapeutics are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Cidara Therapeutics i.e., Cidara Therapeutics and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Cidara Therapeutics and Protalix Biotherapeutics

Given the investment horizon of 90 days Cidara Therapeutics is expected to generate 0.96 times more return on investment than Protalix Biotherapeutics. However, Cidara Therapeutics is 1.04 times less risky than Protalix Biotherapeutics. It trades about 0.12 of its potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.09 per unit of risk. If you would invest  1,241  in Cidara Therapeutics on August 30, 2024 and sell it today you would earn a total of  779.00  from holding Cidara Therapeutics or generate 62.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Cidara Therapeutics  vs.  Protalix Biotherapeutics

Cidara Therapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Protalix Biotherapeutics

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Cidara Therapeutics and Protalix Biotherapeutics

The main advantage of trading using opposite Cidara Therapeutics and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cidara Therapeutics position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.

The idea behind Cidara Therapeutics and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.